Skip to content
zameds

Xenara

Cephalexin

Every registration of this product has been cancelled.

Loading the molecular structure
C16H17N3O4S347.40 g/mol

(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 27447.

Registration

Applicants
1
Registrations
2

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Aurogen South Africa (Pty) LtdCancelledXenara125 mg/5 ml, 250 mg/5 ml550158.156, 550159.157Not determinedNone

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Xenara oral suspension 125 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS: CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 125,0 mg

125 mg/5 mlOral suspension550158.15655/20.1.1/0158.156CancelledNot determinedNone
Xenara oral suspension 250 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS: CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 250,0 mg

250 mg/5 mlOral suspension550159.15755/20.1.1/0159.157CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading...
Loading PubMed articles